Brooks Laboratories Ltd
NSE:BROOKS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
73.8
176.75
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Brooks Laboratories Ltd
Brooks Laboratories Ltd
Cash & Cash Equivalents
Brooks Laboratories Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Brooks Laboratories Ltd
NSE:BROOKS
|
Cash & Cash Equivalents
₹1.3m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
-42%
|
|
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
Cash & Cash Equivalents
₹3.4B
|
CAGR 3-Years
-46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Suven Life Sciences Ltd
NSE:SUVEN
|
Cash & Cash Equivalents
₹924.9m
|
CAGR 3-Years
100%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Dishman Carbogen Amcis Ltd
NSE:DCAL
|
Cash & Cash Equivalents
₹3.9B
|
CAGR 3-Years
18%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Syngene International Ltd
NSE:SYNGENE
|
Cash & Cash Equivalents
₹2.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
I
|
Innova Captab Ltd
NSE:INNOVACAP
|
Cash & Cash Equivalents
₹117.3m
|
CAGR 3-Years
35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Brooks Laboratories Ltd
Glance View
Brooks Laboratories Ltd. is a research and development driven pharmaceutical manufacturing company. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2011-09-02. The firm operates through the Pharmaceuticals segment. The company manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup and eye/ear drops. Its products under Carbapenem category includes Imipenem 250mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 125mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, Doripenem 500mg and Doripenem 1000mg. The company offers Penicillins in the form of injections, tablets and dry syrup. Its General category of products include liquid injections, dry powder injections and eye/ear drops. The firm has two manufacturing plants, which are located at Baddi in Himachal Pradesh and Vadodara in Gujarat. The firm manufactures and markets the pharmaceuticals nationally and internationally to various regulated markets.
See Also
What is Brooks Laboratories Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.3m
INR
Based on the financial report for Jun 30, 2024, Brooks Laboratories Ltd's Cash & Cash Equivalents amounts to 1.3m INR.
What is Brooks Laboratories Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-42%
Over the last year, the Cash & Cash Equivalents growth was 441%. The average annual Cash & Cash Equivalents growth rates for Brooks Laboratories Ltd have been -58% over the past three years , -48% over the past five years , and -42% over the past ten years .
You don't have any saved screeners yet
